The DOI matches its Crossref record; 54 of the 54 references it cites were found in a registry or an index.
Genetic Inactivation of CD33 in Hematopoietic Stem Cells to Enable CAR T Cell Immunotherapy for Acute Myeloid Leukemia
Open accessAbstract
Summary The absence of cancer-restricted surface markers is a major impediment to antigen-specific immunotherapy using chimeric antigen receptor (CAR) T cells. For example, targeting the canonical myeloid marker CD33 in acute myeloid leukemia (AML) results in toxicity from destruction of normal myeloid cells. We hypothesized that a leukemia-specific antigen could be created by deleting CD33 from normal hematopoietic stem and progenitor cells (HSPC), thereby generating a hematopoietic system resistant to CD33-targeted therapy and enabling specific targeting of AML with CAR T cells. We generated CD33-deficient human HSPC and demonstrated normal engraftment and differentiation in immunodeficient mice. Autologous CD33 KO HSPC transplantation in rhesus macaques demonstrated long-term multilineage engraftment of gene-edited cells, with normal myeloid function. CD33-deficient cells were impervious to CD33-targeting CAR T cells, allowing for efficient elimination of leukemia without myelotoxicity. These studies illuminate a novel approach to antigen-specific immunotherapy by genetically engineering the host to avoid on-target, off-tumor toxicity.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Multiplex Genome Engineering Using CRISPR/Cas Systems
Cong, L., Ran, F. A., Cox, D., Lin, S., Barretto, R., Habib, N., Hsu, P. D., Wu, X., Jiang, W., Marraffini, L. A., et al. (2013) · Science · doi:10.1126/science.1231143 · Cited by 15,339
Analysis of protein-coding genetic variation in 60,706 humans
Exome Aggregation Consortium, Lek, M., Karczewski, K. J., Minikel, E. V., Samocha, K. E., Banks, E., Fennell, T., O’Donnell-Luria, A. H., Ware, J. S., Hill, A. J., et al. (2016) · Nature · doi:10.1038/nature19057 · Cited by 9,587
Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia
Maude, S. L., Frey, N., Shaw, P. A., Aplenc, R., Barrett, D. M., Bunin, N. J., Chew, A., Gonzalez, V. E., Zheng, Z., Lacey, S. F., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1407222 · Cited by 5,413
DNA targeting specificity of RNA-guided Cas9 nucleases
Hsu, P. D., Scott, D. A., Weinstein, J. A., Ran, F. A., Konermann, S., Agarwala, V., Li, Y., Fine, E. J., Wu, X., Shalem, O., et al. (2013) · Nature Biotechnology · doi:10.1038/nbt.2647 · Cited by 4,741
Lee, D. W., Kochenderfer, J. N., Stetler-Stevenson, M., Cui, Y. K., Delbrook, C., Feldman, S. A., Fry, T. J., Orentas, R., Sabatino, M., Shah, N. N., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(14)61403-3 · Cited by 2,898
Efficacy and Toxicity Management of 19-28z CAR T Cell Therapy in B Cell Acute Lymphoblastic Leukemia
Davila, M. L., Riviere, I., Wang, X., Bartido, S., Park, J., Curran, K., Chung, S. S., Stefanski, J., Borquez-Ojeda, O., Olszewska, M., et al. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3008226 · Cited by 2,476
Easy quantitative assessment of genome editing by sequence trace decomposition
Brinkman, E. K., Chen, T., Amendola, M., & van Steensel, B. (2014) · Nucleic Acids Research · doi:10.1093/nar/gku936 · Cited by 2,390
Data-Driven Phenotypic Dissection of AML Reveals Progenitor-like Cells that Correlate with Prognosis
Levine, J. H., Simonds, E. F., Bendall, S. C., Davis, K. L., Amir, E.-A. D., Tadmor, M. D., Litvin, O., Fienberg, H. G., Jager, A., Zunder, E. R., et al. (2015) · Cell · doi:10.1016/j.cell.2015.05.047 · Cited by 2,303
CD19 CAR–T cells of defined CD4+:CD8+ composition in adult B cell ALL patients
Turtle, C. J., Hanafi, L.-A., Berger, C., Gooley, T. A., Cherian, S., Hudecek, M., Sommermeyer, D., Melville, K., Pender, B., Budiarto, T. M., et al. (2016) · Journal of Clinical Investigation · doi:10.1172/jci85309 · Cited by 2,112
Improving CRISPR-Cas nuclease specificity using truncated guide RNAs
Fu, Y., Sander, J. D., Reyon, D., Cascio, V. M., & Joung, J. K. (2014) · Nature Biotechnology · doi:10.1038/nbt.2808 · Cited by 1,993
Rational design of highly active sgRNAs for CRISPR-Cas9-mediated gene inactivation
Doench, J. G., Hartenian, E., Graham, D. B., Tothova, Z., Hegde, M., Smith, I., Sullender, M., Ebert, B. L., Xavier, R. J., & Root, D. E. (2014) · Nature Biotechnology · doi:10.1038/nbt.3026 · Cited by 1,617
Kochenderfer, J. N., Dudley, M. E., Kassim, S. H., Somerville, R. P. T., Carpenter, R. O., Stetler-Stevenson, M., Yang, J. C., Phan, G. Q., Hughes, M. S., Sherry, R. M., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.56.2025 · Cited by 1,595
Sotillo, E., Barrett, D. M., Black, K. L., Bagashev, A., Oldridge, D., Wu, G., Sussman, R., Lanauze, C., Ruella, M., Gazzara, M. R., et al. (2015) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-1020 · Cited by 1,254
Self-citationMilone, M. C., Fish, J. D., Carpenito, C., Carroll, R. G., Binder, G. K., Teachey, D., Samanta, M., Lakhal, M., Gloss, B., Danet-Desnoyers, G., et al. (2009) · Molecular Therapy · doi:10.1038/mt.2009.83 · Cited by 1,197
CCTop: An intuitive, flexible and reliable CRISPR/Cas9 target prediction tool
Stemmer, M., Thumberger, T., del Sol Keyer, M., Wittbrodt, J., & Mateo, J. L. (2015) · PLoS ONE · doi:10.1371/journal.pone.0124633 · Cited by 1,088
Extracting a cellular hierarchy from high-dimensional cytometry data with SPADE
Qiu, P., Simonds, E. F., Bendall, S. C., Gibbs, K. D., Bruggner, R. V., Linderman, M. D., Sachs, K., Nolan, G. P., & Plevritis, S. K. (2011) · Nature Biotechnology · doi:10.1038/nbt.1991 · Cited by 956
Isolation of Single Human Hematopoietic Stem Cells Capable of Long-Term Multilineage Engraftment
Notta, F., Doulatov, S., Laurenti, E., Poeppl, A., Jurisica, I., & Dick, J. E. (2011) · Science · doi:10.1126/science.1201219 · Cited by 919
CIRCLE-Seq: A highly sensitive in vitro screen for genome-wide CRISPR-cas9 nuclease off-targets
Tsai, S. Q., Nguyen, N. T., Malagon-Lopez, J., Topkar, V. V., Aryee, M. J., & Joung, J. K. (2017) · Nature Methods · doi:10.1038/nmeth.4278 · Cited by 814
Self-citationEfficient genome modification by CRISPR-Cas9 nickase with minimal off-target effects
Shen, B., Zhang, W., Zhang, J., Zhou, J., Wang, J., Chen, L., Wang, L., Hodgkins, A., Iyer, V., Huang, X., et al. (2014) · Nature Methods · doi:10.1038/nmeth.2857 · Cited by 769
Normalization of mass cytometry data with bead standards
Finck, R., Simonds, E. F., Jager, A., Krishnaswamy, S., Sachs, K., Fantl, W., Pe'er, D., Nolan, G. P., & Bendall, S. C. (2013) · Cytometry Part A · doi:10.1002/cyto.a.22271 · Cited by 761
Zunder, E. R., Finck, R., Behbehani, G. K., Amir, E.-A. D., Krishnaswamy, S., Gonzalez, V. D., Lorang, C. G., Bjornson, Z., Spitzer, M. H., Bodenmiller, B., et al. (2015) · Nature Protocols · doi:10.1038/nprot.2015.020 · Cited by 596
Self-citationTargeted genome editing in human repopulating haematopoietic stem cells
Genovese, P., Schiroli, G., Escobar, G., Di Tomaso, T., Firrito, C., Calabria, A., Moi, D., Mazzieri, R., Bonini, C., Holmes, M. C., et al. (2014) · Nature · doi:10.1038/nature13420 · Cited by 555
Web‐Based Analysis and Publication of Flow Cytometry Experiments
Kotecha, N., Krutzik, P. O., & Irish, J. M. (2010) · Current Protocols in Cytometry · doi:10.1002/0471142956.cy1017s53 · Cited by 511
Gill, S., Tasian, S. K., Ruella, M., Shestova, O., Li, Y., Porter, D. L., Carroll, M., Danet-Desnoyers, G., Scholler, J., Grupp, S. A., et al. (2014) · Blood · doi:10.1182/blood-2013-09-529537 · Cited by 489
Self-citationKenderian, S. S., Ruella, M., Shestova, O., Klichinsky, M., Aikawa, V, Morrissette, J. J. D., Scholler, J., Song, D., Porter, D. L., Carroll, M., et al. (2015) · Leukemia · doi:10.1038/leu.2015.52 · Cited by 426
Self-citationWang, Q.-S., Wang, Y., Lv, H.-Y., Han, Q.-W., Fan, H., Guo, B., Wang, L.-L., & Han, W.-D. (2015) · Molecular Therapy · doi:10.1038/mt.2014.164 · Cited by 418
Mardiros, A., Dos Santos, C., McDonald, T., Brown, C. E., Wang, X., Budde, L. E., Hoffman, L., Aguilar, B., Chang, W.-C., Bretzlaff, W., et al. (2013) · Blood · doi:10.1182/blood-2012-12-474056 · Cited by 374
Taussig, D. C. (2005) · Blood · doi:10.1182/blood-2005-03-1072 · Cited by 370
Human knockouts and phenotypic analysis in a cohort with a high rate of consanguinity
Saleheen, D., Natarajan, P., Armean, I. M., Zhao, W., Rasheed, A., Khetarpal, S. A., Won, H.-H., Karczewski, K. J., O’Donnell-Luria, A. H., Samocha, K. E., et al. (2017) · Nature · doi:10.1038/nature22034 · Cited by 340
Pizzitola, I., Anjos-Afonso, F., Rouault-Pierre, K., Lassailly, F., Tettamanti, S., Spinelli, O., Biondi, A., Biagi, E., & Bonnet, D. (2014) · Leukemia · doi:10.1038/leu.2014.62 · Cited by 287
Health and population effects of rare gene knockouts in adult humans with related parents
Narasimhan, V. M., Hunt, K. A., Mason, D., Baker, C. L., Karczewski, K. J., Barnes, M. R., Barnett, A. H., Bates, C., Bellary, S., Bockett, N. A., et al. (2016) · Science · doi:10.1126/science.aac8624 · Cited by 286
Biasco, L., Pellin, D., Scala, S., Dionisio, F., Basso-Ricci, L., Leonardelli, L., Scaramuzza, S., Baricordi, C., Ferrua, F., Cicalese, M. P., et al. (2016) · Cell stem cell · doi:10.1016/j.stem.2016.04.016 · Cited by 243
Identification of a large set of rare complete human knockouts
Sulem, P., Helgason, H., Oddson, A., Stefansson, H., Gudjonsson, S. A., Zink, F., Hjartarson, E., Sigurdsson, G. T., Jonasdottir, A., Jonasdottir, A., et al. (2015) · Nature Genetics · doi:10.1038/ng.3243 · Cited by 220
Paul, S. P., Taylor, L. S., Stansbury, E. K., & McVicar, D. W. (2000) · Blood · doi:10.1182/blood.v96.2.483 · Cited by 204
Paul, S. P., Taylor, L. S., Stansbury, E. K., & McVicar, D. W. (2000) · Blood · doi:10.1182/blood.v96.2.483.014k40_483_490 · Cited by 202
The past and future of CD33 as therapeutic target in acute myeloid leukemia
Laszlo, G. S., Estey, E. H., & Walter, R. B. (2014) · Blood Reviews · doi:10.1016/j.blre.2014.04.001 · Cited by 192
Wu, C., Li, B., Lu, R., Koelle, S. J., Yang, Y., Jares, A., Krouse, A. E., Metzger, M., Liang, F., Loré, K., et al. (2014) · Cell Stem Cell · doi:10.1016/j.stem.2014.01.020 · Cited by 186
Self-citationTaylor, V. C., Buckley, C. D., Douglas, M., Cody, A. J., Simmons, D. L., & Freeman, S. D. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.17.11505 · Cited by 186
Gemtuzumab ozogamicin for acute myeloid leukemia
Appelbaum, F. R., & Bernstein, I. D. (2017) · Blood · doi:10.1182/blood-2017-09-797712 · Cited by 184
Cao, H., & Crocker, P. R. (2011) · Immunology · doi:10.1111/j.1365-2567.2010.03368.x · Cited by 170
Tashiro, H., Sauer, T., Shum, T., Parikh, K., Mamonkin, M., Omer, B., Rouce, R. H., Lulla, P., Rooney, C. M., Gottschalk, S., et al. (2017) · Molecular Therapy · doi:10.1016/j.ymthe.2017.05.024 · Cited by 160
An anti-CD3/anti–CLL-1 bispecific antibody for the treatment of acute myeloid leukemia
Leong, S. R., Sukumaran, S., Hristopoulos, M. L., Tótpál, K., Stainton, S. L., Lu, E., Wong, A., Tam, L., Newman, R., Vuillemenot, B. R., et al. (2016) · Blood · doi:10.1182/blood-2016-08-735365 · Cited by 156
CD33/Siglec-3 Binding Specificity, Expression Pattern, and Consequences of Gene Deletion in Mice
der Linden, E. C. M. B.-V., Angata, T., Reynolds, S. A., Powell, L. D., Hedrick, S. Μ., & Varki, A. P. (2003) · Molecular and Cellular Biology · doi:10.1128/mcb.23.12.4199-4206.2003 · Cited by 136
Yang, L., Grishin, D., Wang, G., Aach, J., Zhang, C.-Z., Chari, R., Homsy, J. G., Cai, X., Zhao, Y., Fan, J.-B., et al. (2014) · Nature Communications · doi:10.1038/ncomms6507 · Cited by 133
The sialoadhesin CD33 is a myeloid-specific inhibitory receptor
Ulyanova, T., Blasioli, J., Woodford-Thomas, T. A., & Thomas, M. L. (1999) · European Journal of Immunology · doi:10.1002/(sici)1521-4141(199911)29:11<3440::aid-immu3440>3.0.co;2-c · Cited by 129
Implications of human genetic variation in CRISPR-based therapeutic genome editing
Scott, D. A., & Zhang, F. (2017) · Nature Medicine · doi:10.1038/nm.4377 · Cited by 129
Ornatsky, O., Kinach, R., Bandura, D. R., Lou, X., Tanner, S. D., Baranov, V. I., Nitz, M., & Winnik, M. A. (2008) · Journal of Analytical Atomic Spectrometry · doi:10.1039/b710510j · Cited by 125
Behbehani, G. K., Samusik, N., Bjornson, Z. B., Fantl, W. J., Medeiros, B. C., & Nolan, G. P. (2015) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-0298 · Cited by 109
Self-citationDutour, A., Marin, V., Pizzitola, I., Valsesia‐Wittmann, S., Lee, D. A., Yvon, E. S., Finney, H. M., Lawson, A. D. G., Brenner, M. K., Biondi, A., et al. (2012) · Advances in Hematology · doi:10.1155/2012/683065 · Cited by 105
Peterson, C. W., Wang, J., Norman, K. K., Norgaard, Z. K., Humbert, O., Tse, C. K., Yan, J. J., Trimble, R. G., Shivak, D. A., Rebar, E. J., et al. (2016) · Blood · doi:10.1182/blood-2015-09-672337 · Cited by 69
Myeloid precursors and acute myeloid leukemia cells express multiple CD33-related Siglecs
Nguyen, D., Ball, E. D., & Varki, A. P. (2006) · Experimental Hematology · doi:10.1016/j.exphem.2006.03.003 · Cited by 64
Ishida, A., Akita, K., Mori, Y., Tanida, S., Toda, M., Inoue, M., & Nakada, H. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.523480 · Cited by 50
Large Animal Models for Stem and Progenitor Cell Analysis
Donahue, R. E., Kuramoto, K., & Dunbar, C. E. (2005) · Current Protocols in Immunology · doi:10.1002/0471142735.im22a01s69 · Cited by 41
Self-citationGeographic clonal tracking in macaques provides insights into HSPC migration and differentiation
Wu, C., Espinoza, D. A., Koelle, S., Potter, E. L., Lu, R., Li, B., Yang, D., Fan, X., Donahue, R. E., Roederer, M., et al. (2017) · The Journal of Experimental Medicine · doi:10.1084/jem.20171341 · Cited by 37
Self-citation
Cited by
Engineering strategies to overcome the current roadblocks in CAR T cell therapy
Rafiq, S., Hackett, C. S., & Brentjens, R. J. (2020) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-019-0297-y · Cited by 1,472
Advances in cancer immunotherapy 2019 – latest trends
Kruger, S., Ilmer, M., Kobold, S., Cadilha, B. L., Endres, S., Ormanns, S., Schuebbe, G., Renz, B. W., D’Haese, J. G., Schloesser, H., et al. (2019) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-019-1266-0 · Cited by 563
Acute myeloid leukemia: 2023 update on diagnosis, risk‐stratification, and management
Shimony, S., Stahl, M., & Stone, R. M. (2023) · American Journal of Hematology · doi:10.1002/ajh.26822 · Cited by 448
Advances in acute myeloid leukemia
Newell, L. F., & Cook, R. J. (2021) · BMJ · doi:10.1136/bmj.n2026 · Cited by 440
Recent advances in CAR-T cell engineering
Huang, R., Li, X., He, Y., Zhu, W., Gao, L., Liu, Y., Gao, L., Wen, Q., Zhong, J. F., Zhang, C., et al. (2020) · Journal of Hematology & Oncology · doi:10.1186/s13045-020-00910-5 · Cited by 402
Metadata
- Authors
- Kim, M. Y., Yu, K.-R., Kenderian, S. S., Ruella, M., Chen, S., Shin, T.-H., Aljanahi, A. A., Schreeder, D., Klichinsky, M., Shestova, O., Kozlowski, M. S., Cummins, K. D., Shan, X., Shestov, M., Bagg, A., Morrissette, J. J. D., Sekhri, P., Lazzarotto, C. R., Calvo, K. R., Kuhns, D. B., Donahue, R. E., Behbehani, G. K., Tsai, S. Q., Dunbar, C. E., & Gill, S.
- Venue
- Cell
- Publisher
- Elsevier BV
- Published
- 2018-05
- Volume
- 173
- Issue
- 6
- Pages
- 1439-1453.e19
- ISSN
- 0092-8674 (ISSN-L)
- OpenAlex
- W2805058565
- Cited by
- 459
- References
- 54
- FWCI
- 16.09
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.